MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus

Cancer Gene Therapy

Volumn 21, Issue 9, 2014, Pages 373-380

  Baertsch, M A ^a   Leber, M F ^a   Bossow, S ^a   Singh, M ^a   Engeland, C E ^a   Albert, J ^a   Grossardt, C ^a   Jager D ^b   Von Kalle, C ^a   Ungerechts, G ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 148A; MICRORNA 7; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL; LIVER SLICE; MICRORNA TARGET SITE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; ORGANS AT RISK; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; RNA STRUCTURE; TUMOR XENOGRAFT; VERO CELL LINE; VIRUS TITRATION; ADMINISTRATION AND DOSAGE; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; CYTOPATHOGENIC EFFECT; DISEASE MODEL; DRUG SCREENING; FEMALE; GENE ORDER; GENE SILENCING; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; MEASLES VIRUS; MOLECULAR GENETICS; MORTALITY; NEOPLASMS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REPORTER GENE; RNA INTERFERENCE; TUMOR CELL LINE; VIRUS REPLICATION;

MEASLES VIRUS;

ANIMALS; BASE SEQUENCE; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE ORDER; GENES, REPORTER; GENETIC VECTORS; HUMANS; MEASLES VIRUS; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASMS; ONCOLYTIC VIRUSES; RNA INTERFERENCE; TRANSDUCTION, GENETIC; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926609945     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.40     Document Type: Article

References (41)

1. Galanis E, Hartmann L, Cliby W, Long H, Peethambaram P, Barrette B et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70: 875-882.
2. Russell SJ, Federspiel MJ, Peng K, Tong C, Dingli D, Morice WG et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89 (7): 926-933.
3. Esolen LM, Park SW, Hardwick JM, Griffin DE.. Apoptosis as a cause of death in measles virus-infected cells. J Virol 1995; 69: 3955-3958.
4. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2014; 12: 23-34.
5. Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011; 18(8): 598-608.
6. Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF et al. Granulocyte-macrophage colony-stimulating factor-Armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24: 644-654.
7. Leber M, Bossow S, Leonard V, Zaoui K, Grossardt C, Frenzke M et al. MicroRNAsensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther 2011; 19: 1097-1106.
8. Ungerechts G, Frenzke ME, Yaiw K, Miest T, Johnston PB, Cattaneo R. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Therapy 2010; 17: 1506-1516.
9. Miest T, Yaiw K, Frenzke M, Lampe J, Hudacek A, Springfeld C et al. Envelopechimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther 2011; 19: 1813-1820.
10. Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P et al. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. J Invest Dermatol 2013; 133: 1034-1042.
11. Navaratnarajah CK, Miest TS, Carfi A, Cattaneo R. Targeted entry of enveloped viruses: measles and herpes simplex virus I. Curr Opin Virol 2012; 2: 43-49.
12. Ungerechts G, Springfeld C, Frenzke M, Lampe J, Johnston P, Parker W et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-Armed measles virus can synergize with fludarabine. Cancer Res 2007; 67: 10939-10947.
13. Ungerechts G, Springfeld C, Frenzke M, Lampe J, Parker W, Sorscher E et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15: 1991-1997.
14. Friedrich K, Hanauer JR, Prufer S, Munch RC, Volker I, Filippis C et al. DARPintargeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther 2013; 21: 849-859.
15. Hudacek AW, Navaratnarajah CK, Cattaneo R. Development of measles virusbased shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins. Cancer Gene Ther 2013; 20: 109-116.
16. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC. A let-7 MicroRNAsensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther 2008; 16: 1437-1443.
17. Kelly E, Hadac E, Greiner S, Russell S. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 2008; 14: 1278-1283.
18. Kelly EJ, Nace R, Barber GN, Russell SJ. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 2010; 84: 1550-1562.
19. Lee Cleo Y F, Rennie PS, Jia WW. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res 2009; 15: 5126-5135.
20. Ylosmaki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, Saksela K. Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 2008; 82: 11009-11015.
21. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007; 82: 700-710.
22. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia M et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113.
23. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-678.
24. Bai S, Nasser M, Wang B, Hsu S, Datta J, Kutay H et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027.
25. Fu X, Rivera A, Tao L, De G, Zhang X. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol Ther 2011; 20(2): 339-346.
26. Ylosmaki E, Lavilla-Alonso S, Jaamaa S, Vaha-Koskela M, af Hallstrom T, Hemminki A et al. MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver. PLoS One 2013; 8: e54506.
27. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452.
28. Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-1908.
29. Mestdagh P, Lefever S, Pattyn F, Ridzon D, Fredlund E, Fieuw A et al. The microRNA body map: dissecting microRNA function through integrative genomics. Nucleic Acids Res 2011; 39: e136.
30. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14: 5773-5784.
31. Muhlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KO, Cattaneo R et al. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-Activatable oncolytic measles virus. Cancer Res 2010; 70: 7620-7629.
32. Zimmermann M, Weiland T, Bitzer M, Lauer UM. Preclinical testing of virotherapeutics for primary and secondary tumors of the liver. Methods Mol Biol 2012; 806: 121-136.
33. Rima BK, Duprex WP. The measles virus replication cycle. Curr Top Microbiol Immunol 2009; 329: 77-102.
34. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99-110.
35. Wild TF, Buckland R. Functional aspects of envelope-Associated measles virus proteins. Curr Top Microbiol Immunol 1995; 191: 51-64.
36. Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol 1991; 72(Pt 2): 439-442.
37. Russell SJ, Peng K, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
38. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414.
39. Hsu S, Chu C, Tsou A, Chen S, Chen H, Hsu PW et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 2008; 36: D165-D169.
40. Sugio K, Sakurai F, Katayama K, Tashiro K, Matsui H, Kawabata K et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res 2011; 17: 2807-2818.
41. Negrini M, Gramantieri L, Sabbioni S, Croce CM. microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11: 500-521.